Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS)

NCT04624659 is registered in ClinicalTrials.gov with Forma Therapeutics, Inc. as lead sponsor.

NCT NCT04624659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04624659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS)
Lead sponsor
Forma Therapeutics, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 29, 2021
Completion date
March 19, 2027
Enrollment
450 (estimated)
Sites
142

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease